Instituto de Investigacion en Ciencias Biomedicas, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Department of Medicine/Section of Rheumatology, Yale University School of Medicine, New Haven, United States.
Curr Mol Med. 2018;18(10):679-688. doi: 10.2174/1566524019666190129123240.
Macrophage migration inhibitory factor (MIF) is an immunoregulatory cytokine that plays a crucial role as a regulator of the innate and adaptive immune responses and takes part in the destructive process of the joint in rheumatoid arthritis (RA) by promoting angiogenesis and inducing proinflammatory cytokines and matrix metalloproteinases (MMP). We evaluated if recombinant human MIF (rhMIF) induces the production of TNF-α, IFN-γ, IL-1β, IL-6, IL-10, IL-17A, and IL- 17F in peripheral blood mononuclear cells (PBMC) from RA patients and control subjects (CS).
The PBMC from RA patients and CS were stimulated for 24 hours with combinations of LPS, rhMIF or the MIF antagonist ISO-1. Cytokine profiles were measured using a multiplex immunoassay and, macrophage migration inhibitory factor (MIF) was determined by ELISA kit.
The PBMC of CS and RA produced Th1 and Th17 cytokines under stimulation with rhMIF, however, this effect was higher in the cells of RA patients. The rhMIFstimulated PBMC from RA patients produced higher levels of Th1 and Th17 cytokines in comparison with unstimulated cells: TNF-α (538.81 vs. 5.02 pg/mL, p<0.001), IFN-γ (721.90 vs. 8.40 pg/mL, p<0.001), IL-1β (150.14 vs. 5.17 pg/mL, p<0.05), IL-6 (19769.70 vs. 119.85 pg/mL, p<0.001), IL-17A (34.97 vs. 0.90 pg/mL, p<0.01) and IL-17F (158.43 vs. 0.92 pg/mL, p<0.001).
These results highlight the potential role of MIF in the establishment of the chronic inflammatory process in RA via Th1 and Th17 cytokine profile induction and provide new evidence of the role of MIF to stimulate the IL-17A and IL-17F expression in PBMC from RA and CS.
巨噬细胞移动抑制因子(MIF)是一种免疫调节细胞因子,作为先天和适应性免疫反应的调节剂发挥着关键作用,并通过促进血管生成和诱导前炎性细胞因子和基质金属蛋白酶(MMP)参与类风湿关节炎(RA)关节的破坏过程。我们评估了重组人 MIF(rhMIF)是否会诱导 RA 患者和对照受试者(CS)的外周血单个核细胞(PBMC)产生 TNF-α、IFN-γ、IL-1β、IL-6、IL-10、IL-17A 和 IL-17F。
用 LPS、rhMIF 或 MIF 拮抗剂 ISO-1 组合刺激 RA 患者和 CS 的 PBMC 24 小时。使用多重免疫测定法测量细胞因子谱,并通过 ELISA 试剂盒测定巨噬细胞移动抑制因子(MIF)。
CS 和 RA 的 PBMC 在 rhMIF 刺激下产生 Th1 和 Th17 细胞因子,但 RA 患者的细胞中这种作用更高。与未刺激的细胞相比,rhMIF 刺激的 RA 患者的 PBMC 产生更高水平的 Th1 和 Th17 细胞因子:TNF-α(538.81 与 5.02 pg/mL,p<0.001)、IFN-γ(721.90 与 8.40 pg/mL,p<0.001)、IL-1β(150.14 与 5.17 pg/mL,p<0.05)、IL-6(19769.70 与 119.85 pg/mL,p<0.001)、IL-17A(34.97 与 0.90 pg/mL,p<0.01)和 IL-17F(158.43 与 0.92 pg/mL,p<0.001)。
这些结果突出了 MIF 通过诱导 Th1 和 Th17 细胞因子谱在 RA 中建立慢性炎症过程中的潜在作用,并提供了 MIF 刺激 RA 和 CS 的 PBMC 中 IL-17A 和 IL-17F 表达的新证据。